NCT06256055View on ClinicalTrials.gov

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

April 30, 2025

Conditions
Malignant MesotheliomaColorectal CancerBile Duct CancerRectal CancerOvary CancerPancreatic CancerBreast Cancer Female
Interventions
BIOLOGICAL

UCMYM802 Injection

1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.

Trial Locations (1)

Unknown

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

UTC Therapeutics Inc.

INDUSTRY